The ALKBH3 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human lung adenocarcinoma A-549 cell line. This product provides a heterogeneous pool of cells with targeted disruption of the ALKBH3 gene, enabling functional studies without clonal selection biases. As a polyclonal knockout model, it facilitates robust interrogation of ALKBH3-dependent DNA and RNA repair processes in a cancer-relevant background.
A-549 cells, established from a 58-year-old Caucasian male with lung adenocarcinoma, are an adherent epithelial line widely used to model type II pneumocyte-derived lung adenocarcinoma. They maintain key alveolar epithelial characteristics and are extensively applied in oncology research for studying lung cancer biology, signaling, and stress responses. This host cell background provides a clinically pertinent system for examining repair pathway contributions to tumorigenesis and therapy resistance.
ALKBH3 is a Fe(II)/2-oxoglutarate-dependent dioxygenase that repairs alkylation damage by demethylating N1-methyladenine and N3-methylcytosine in DNA and RNA. Transcription of ALKBH3 is regulated by HIF-1?? and SP1, and the protein interacts with PCNA and RNA polymerase II, linking repair to replication and transcription. It functions within direct reversal repair and cross-talks with base excision repair components such as ALKBH2, MGMT, APE1, POLB, and XRCC1. ALKBH3-mediated RNA demethylation also modulates mRNA stability and translation, thus protecting cells from alkylation-induced cytotoxicity and mutagenesis. Disruption of ALKBH3 results in accumulation of unrepaired lesions and altered gene expression profiles.
In the A-549 lung adenocarcinoma model, ALKBH3 knockout sensitizes cells to alkylating chemotherapeutics, underscoring its role in drug resistance. This model mirrors the defective DNA repair commonly found in non-small cell lung cancers, where ALKBH3 expression correlates with tumor aggressiveness. The polyclonal knockout population recapitulates tumor heterogeneity, making it ideal for dissecting crosstalk between repair pathways and cell survival, and for identifying synthetic lethal interactions with other repair inhibitors.
Key applications include colony formation assays with methylating agents (e.g., temozolomide) to assess drug sensitivity, ??-H2AX immunofluorescence for DNA damage quantification, and RT-qPCR for repair gene expression. The model is also suited for RNA immunoprecipitation and RNA-seq to investigate ALKBH3-dependent RNA modifications. It supports cancer biology research, drug resistance screening, and combination therapy evaluation. For more information, please contact Ascent Research.
